Wesail Biotech
Wesail Biotech is a privately held Chinese IVD manufacturer (founded 2019, Dongguan) operating four diagnostic platforms — immunofluorescence, colloidal gold, chemiluminescence, and PCR — selling 40+ reagent tests and matching POCT analyzers to hospitals, clinical labs, and distributors across 40+ countries.
- Company typePrivate
- Founded2019
- HeadquartersDongguan, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Wesail Biotech does
Wesail Biotech (legal entity: Guangdong Weishi Biotechnology Co., Ltd.) is a privately held Chinese in vitro diagnostics (IVD) manufacturer founded in December 2019 and headquartered in Dongguan, Guangdong Province. The company operates four application platforms — Immunofluorescence (FIA), Colloidal Gold (Rapid Test), Chemiluminescence Immunoassay (CLIA), and PCR & Sequencing (the last under development) — producing both diagnostic reagents and the matching fluorescence/immunochemistry analyzers that run them. Its reagent portfolio spans roughly 40+ products across 14 disease categories, with particular depth in cardiac markers (hs-cTnI, CK-MB, Myoglobin, BNP, NT-proBNP, H-FABP, D-Dimer), inflammation (IL-6, PCT, SAA, Hs-CRP), infectious disease (COVID-19 antigen/antibody/saliva, Monkeypox, H. pylori), diabetes, thyroid, renal function, bone metabolism, gastric function, pregnancy/reproduction, anemia, brain injury, and cancer markers. Hardware offerings include the WS-Mi6000 multi-channel fluorescence analyzer (180 samples/hour), WS-Si1000 single-channel analyzer (up to 150 T/h), WS-Si1300 handheld dual-detection (fluorescence + colloidal gold), and the WS-i60 reagent card incubator, all supporting LIS connectivity via WIFI/Bluetooth/USB.
The company monetizes primarily through one-time sale of IVD reagents and hardware instruments (analyzers and incubators) sold to hospitals, clinical labs, ICUs, chest pain centers, stroke centers, and primary care institutions, with quality control products as a secondary stream. Pricing is quote-based and not publicly disclosed. The go-to-market combines direct enterprise field sales with international distribution through channel partners and event-driven demand generation at MEDICA (Germany), CACLP (China), and Medlab Dubai (UAE). Wesail holds 19 NMPA product registration certificates covering nine diagnostic categories, ISO 13485 quality management certification, EU CE marking, TÜV CE0123 self-test certification (4th globally), German PEI performance verification, French ANSM home test whitelist (7th globally), German BfArM whitelist, UK MHRA, and additional approvals in Germany, Russia, Turkey, and France. Products are documented as exported to 40+ countries across EMEA, APAC, LATAM, and MEA, with a 3,000 square meter production base and 140+ domestic and foreign certificates and patents. The company is founder-owned with no disclosed external funding or institutional investors.
Wesail Biotech firmographics
Firmographics- Name
- Wesail Biotech
- Legal name
- Guangdong Weishi Biotechnology Co., Ltd.
- Website
- https://en.wesailbio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Wesail Biotech is a privately held Chinese IVD manufacturer (founded 2019, Dongguan) operating four diagnostic platforms — immunofluorescence, colloidal gold, chemiluminescence, and PCR — selling 40+ reagent tests and matching POCT analyzers to hospitals, clinical labs, and distributors across 40+ countries.
- Ownership category
- akta.pro rank
Wesail Biotech industry classification
Industry- Product category
- In Vitro Diagnostics (IVD)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Wesail Biotech is headquartered
LocationHeadquarters
- HQ city
- Dongguan
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Wesail Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- IVD Reagent Sales: Sale of immunofluorescence, chemiluminescence, and colloidal gold rapid test reagent products covering cardiovascular diseases, infectious diseases, brain injury, kidney injury, thyroid diseases, diabetes, pregnancy, and cancer diagnostics.
- Diagnostic Instrument Sales and Rental: Sale and supply of matching fluorescence immunoassay analyzers (single-channel, multi-channel, handheld) and reagent card incubators for POCT settings.
- Quality Control Products: Sale of quality control products for laboratory use alongside diagnostic reagent products.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Wesail Biotech product offering
Product offeringCore offering
Wesail Biotech is a Chinese in vitro diagnostics (IVD) manufacturer that produces diagnostic reagents and clinical analyzers for hospital laboratories, diagnostic centers, and point-of-care settings. The company sells a comprehensive test menu built on four proprietary technology platforms covering clinical chemistry, immunoassay, hematology, and point-of-care testing, combining instrument placements with recurring reagent consumables.
Product overview
Wesail Biotech (Guangdong Weishi Biotechnology Co., Ltd.) offers a multi-platform diagnostic product portfolio consisting of four technology platforms: Immunofluorescence (FIA), Colloidal Gold, Chemiluminescence (CLIA), and PCR/Sequencing. The product ecosystem comprises four automated/semi-automated analyzer instruments (WS-Mi6000 multi-channel fluorescence analyzer, WS-Si1000 single-channel immunofluorescence analyzer, WS-Si1300 handheld fluorescence immunoassay analyzer, and WS-i60 reagent card incubator) serving as the hardware foundation for 40+ immunofluorescence reagent tests across 14 disease categories including cardiac markers (hs-cTnI, CK-MB, Myoglobin, BNP, NT-proBNP, H-FABP, D-Dimer, Lp-PLA2, ST2), inflammation markers (IL-6, PCT, SAA, Hs-CRP CRP), diabetes markers (HbA1c, Insulin, C Peptide), thyroid function (T3, T4, TSH), renal function (Cys-C, β2-MG, MAU), bone metabolism (Osteocalcin, 25-OH VD), gastric function (PGⅠ, PGⅡ), pregnancy/reproduction (β-HCG, LH, FSH, AMH, PIGF, sFlt-1), anemia (Ferritin), brain injury (S100β), and cancer markers (AFP, PSA, CAA). Additional product lines include COVID-19 antigen/antibody test kits, Monkeypox Virus Ag test kit, and Helicobacter pylori test kit. All instruments support LIS connectivity via WIFI/Bluetooth/USB, enabling integration with laboratory information systems.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Chemistry Diagnostic Reagents and Analyzers Wesail Biotech's clinical chemistry product line consists of diagnostic reagents and dedicated clinical chemistry analyzers for routine biochemistry testing in hospital and clinical laboratories. It is intended for clinical laboratory professionals performing high-volume routine chemistry panels.
- Immunoassay Diagnostic Reagents and Analyzers Wesail Biotech's immunoassay product line provides reagents and immunoassay analyzers for clinical immunology testing in hospital laboratories and diagnostic centers. It is intended for clinical laboratories running hormone, infectious disease, and other immunoassay panels.
- Hematology Diagnostic Reagents and Analyzers Wesail Biotech's hematology product line includes reagents and hematology analyzers used for blood cell analysis in clinical laboratories. It is intended for hospital hematology laboratories and clinical diagnostic centers.
- Point-of-Care Testing (POCT) Reagents and Devices Wesail Biotech's POCT product line provides point-of-care diagnostic reagents and testing devices for use outside central laboratories, such as at the bedside or in outpatient settings. It is intended for hospital point-of-care testing programs and clinical sites requiring rapid diagnostic results.
Quantifiable outcome
- Hs-cTnI detection achieves 79.9% detection rate in healthy population (524 out of 656 tested), meeting high-sensitivity cardiac troponin standards per Chinese Expert Consensus.
- +5 more outcomes
Companies that use Wesail Biotech
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles1 record
Wesail Biotech technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature6 records
Wesail Biotech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- National Center for Clinical Medical Research of Nervous System Diseases (Tiantan Hospital, Capital Medical University)coreStrategic cooperation in the CHANCE-3 clinical research project - a multi-center, randomized, double-blind, parallel-controlled clinical study covering nearly 400 second-level and above hospitals. Wesail's fluorescence immunoassay reagents and instruments were selected as the only POCT product to provide technical support for evaluating colchicine efficacy in stroke prevention.
- Sequoia China FoundationminorSequoia China Foundation donated Wesail's COVID-19 antigen self-test kits to Hong Kong to help fight the fifth wave of the COVID-19 epidemic.
- China Merchants GroupminorChina Merchants Group donated Wesail's COVID-19 antigen self-test kits to Hong Kong as part of their 'China Merchants Warm Estate' community care action.
- Vietnam Local AgentsminorLocal agents in Vietnam partnered with Wesail to donate COVID-19 antigen detection kits to the government of Vietnam for epidemic screening and diagnosis assistance.
- Dongguan Science and Technology BureauminorAs a partner in the project undertaking unit, Wesail participated in the Dongguan City new coronavirus pneumonia epidemic prevention and control technology research project, responsible for research and development of new coronavirus immune POCT reagents. The project aimed to improve Dongguan's epidemic prevention and control capabilities.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Wesail Biotech competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Wesail Biotech social profiles
Digital presenceWesail Biotech compliance and trust
Trust signalCompliance9 records
Wesail Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wesail Biotech leadership team
Management profileNumber of profiles
Profiles1 record
Wesail Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wesail Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wesail Biotech
What does Wesail Biotech do?
Wesail Biotech is a Chinese in vitro diagnostics (IVD) manufacturer that produces diagnostic reagents and clinical analyzers for hospital laboratories, diagnostic centers, and point-of-care settings. The company sells a comprehensive test menu built on four proprietary technology platforms covering clinical chemistry, immunoassay, hematology, and point-of-care testing, combining instrument placements with recurring reagent consumables.
Is Wesail Biotech a public or private company?
Wesail Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Wesail Biotech founded?
Wesail Biotech was founded in 2019. It employs 1 to 10 people.
Where is Wesail Biotech based?
Wesail Biotech is headquartered in Dongguan, China, in the Asia region.
How does Wesail Biotech make money?
Three revenue lines are on record. IVD Reagent Sales are the primary driver. The others are diagnostic Instrument Sales and Rental and quality Control Products.
Does Wesail Biotech have an API?
No public API is recorded for Wesail Biotech.
What industry is Wesail Biotech in?
Wesail Biotech's product category is In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.